Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
(NYSE: TAK) Delayed: 15.47 -0.16 (1.02%)
Previous Close $15.63    52 Week High $0.55 
Open $15.49    52 Week Low $0.55 
Day High $15.60    P/E N/A 
Day Low $15.39    EPS $-0.20 
Volume 2,351,300